Mirum Pharmaceuticals, Inc. (MIRM) Tops Q3 EPS by 6c

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) reported Q3 EPS of ($0.57), $0.06 better than the analyst estimate of ($0.63). Revenue for the quarter came in at $47.7 million versus the consensus estimate of $37.12 million.

For earnings history and earnings-related data on Mirum Pharmaceuticals, Inc. (MIRM) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• MP Materials seen largely insulated after China export-control move
• NVE Corporation names new CEO and expands board to seven members